Literature DB >> 18820708

p53 controls hPar1 function and expression.

Z Salah1, S Haupt, M Maoz, L Baraz, V Rotter, T Peretz, Y Haupt, R Bar-Shavit.   

Abstract

Human protease-activated receptor 1 (hPar1) is a bona fide receptor of the hemostatic protease thrombin, and has a central function in tumor progression. Inactivation of the tumor suppressor gene p53 is one of the most common genomic alterations occurring in cancer. Here, we address the interrelations between p53 and hPar1 in cancer. We demonstrate an inverse correlation between hPar1 gene expression and wild-type (wt) p53 levels, and a direct correlation with levels of the mutant (mt) p53. Bioinformatic search revealed the presence of at least two p53 motifs in the hPar1 promoter. Indeed, temperature-sensitive (ts) p53 forms reduced hPar1 promoter activity on wt p53 expression. Ectopic introduction of the p53R175H mutant into cells lacking p53 caused a moderate two-fold induction of hPar1 promoter activity. Chromatin immunoprecipitation (ChIP) analyses confirmed a physical association between the p53 protein and hPar1 chromatin fragments. In parallel, PAR1 function is attenuated by p53, as shown by inhibition of pFAK levels and a Matrigel invasion assay. Ectopic reinforcement of hPar1 rescued the inhibition conferred by p53, confirming that p53 directly affects hPar1 expression and function. Altogether, we provide evidence for a direct binding between p53 and hPar1 chromatin, and assign hPar1 as a target of p53.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820708     DOI: 10.1038/onc.2008.324

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Protease-activated receptors in hemostasis.

Authors:  Marvin T Nieman
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

2.  Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.

Authors:  Yi Yang; Amanda Stang; Patrick G Schweickert; Nadia A Lanman; Erin N Paul; Brett P Monia; Alexey S Revenko; Joseph S Palumbo; Eric S Mullins; Bennett D Elzey; Edith M Janssen; Stephen F Konieczny; Matthew J Flick
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

Review 3.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

4.  p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells.

Authors:  Shui Ping Tu; Alfred L Chi; Walden Ai; Shigeo Takaishi; Zina Dubeykovskaya; Michael Quante; James G Fox; Timothy C Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-06-18       Impact factor: 4.052

5.  Par genes: molecular probes to pathological assessment in breast cancer progression.

Authors:  Beatrice Uziely; Hagit Turm; Myriam Maoz; Irit Cohen; Bella Maly; Rachel Bar-Shavit
Journal:  Patholog Res Int       Date:  2011-01-24

6.  The transcription factor p53: not a repressor, solely an activator.

Authors:  Martin Fischer; Lydia Steiner; Kurt Engeland
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  HOXA5 and p53 cooperate to suppress lung cancer cell invasion and serve as good prognostic factors in non-small cell lung cancer.

Authors:  Chi-Jen Chang; Yen-Lin Chen; Chia-Hung Hsieh; Ya-Jung Liu; Sung-Liang Yu; Jeremy J W Chen; Chi-Chung Wang
Journal:  J Cancer       Date:  2017-04-09       Impact factor: 4.207

Review 8.  Transcriptional Landscape of PARs in Epithelial Malignancies.

Authors:  Jeetendra Kumar Nag; Rachel Bar-Shavit
Journal:  Int J Mol Sci       Date:  2018-11-02       Impact factor: 5.923

9.  Direct Thrombin Inhibitor Dabigatran Compromises Pulmonary Endothelial Integrity in a Murine Model of Breast Cancer Metastasis to the Lungs; the Role of Platelets and Inflammation-Associated Haemostasis.

Authors:  Marta Smeda; Marta Stojak; Kamil Przyborowski; Magdalena Sternak; Joanna Suraj-Prazmowska; Kamil Kus; Katarzyna Derszniak; Agnieszka Jasztal; Agnieszka Kij; Anna Kurpinska; Anna Kieronska-Rudek; Kamila Wojnar-Lason; Elzbieta Buczek; Tasnim Mohaissen; Stefan Chlopicki
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.